StockWatch
·

Gujarat Kidney and Super Speciality Ltd Q2 FY27 Results

GKSLQ2 FY27 Results
Filing
Result:Steady· Market: Flat

Outlook: Optimistic · Guidance: None

MetricValue (₹ Cr)vs Q1 FY27
Revenue38.0911.1%
Total Income38.6810.6%
Expenditure30.057.3%
PBT8.6223.9%
Net Profit6.6024.0%
OPM26.82%2.39pp
NPM17.06%1.85pp
EPS0.7412.1%
View full financials

No YoY base to judge growth; margins are healthy for a hospital (OPM 26.8%, NPM 17.1%) but absent comparable data this reads as in-line rather than a standout.

GKSL · Q2 FY27 · THE VERDICT

Strong Growth Masks Integration Drag and Cash Flow Anxiety

Q2 revenue and profit soar on acquisition consolidation, but H1 operating cash of just ₹0.4 Cr against ₹11.9 Cr in PAT exposes severe working capital strain. Management declined FY27 guidance, citing 'platform constraints.'

11 Nov 2026 · 6 min read
Q2 Revenue

₹38.1 Cr

+11% QoQ, +195% YoY

Q2 PAT

₹6.6 Cr

+24% QoQ, +129% YoY

Q2 OPM

26.8%

Up from 24.4% in Q1

H1 Operating CF

₹0.4 Cr

vs ₹11.9 Cr PAT

The headline is unmissable: revenue nearly tripled year-on-year, profit more than doubled, margins expanded 240 basis points quarter-on-quarter. On paper, GKSL delivered a flawless quarter. What it didn't deliver was confidence—management refused to offer FY27 guidance despite the momentum. That silence, and the cash numbers beneath the surface, tell a different story.

Where the growth came from

The acquisition consolidation of Blue Tree Dubai polyclinic is real growth, not phantom; the Q2 result field by field matches management's on-call claims. But the growth is acquisition-heavy, not organic. H1 revenue of ₹72.4 Cr includes the full Dubai contribution; capex spend of ₹16.7 Cr was deployed to integrate the acquired platform. Revenue per occupied bed (ARPOB) at ₹9,221 per day is low versus major peers—a conscious trade-off while absorbed hospitals are upgraded to the core Vadodara template, which runs substantially higher margins. Management expects sequential margin improvement as case mix shifts toward super-specialty work (cardiac, orthopedic, renal). Q2's 26.8% operating margin (up from 24.4% in Q1) is early evidence the integration lever is moving, though it remains 600 bps below the pre-acquisition FY26 core of 32.8%.

The cash conversion problem

H1 operating cash flow of ₹0.4 Cr against PAT of ₹11.9 Cr is not a rounding error—it's a gap of ₹11.5 Cr that demands explanation. Management attributed it to acquisition spend; that accounts for part (₹16.7 Cr capex deployed). But the real driver is working capital: receivables have accumulated to ₹40–42 Cr on the balance sheet, locking cash that should flow. Government and insurance payers delay payment routinely by 6+ months; even with tightened collection discipline from 1 April onward, recovery timelines remain uncertain. Until cash conversion demonstrably improves in H2, this gap remains the quarter's most credible concern.

Management's major claims vs. what holds up

Q2 revenue ₹38.1 Cr, up 11% QoQ and 195% YoY

Delivered result: ₹38.1 Cr; QoQ +11.1%, YoY +195%

Supported

Q2 PAT ₹6.6 Cr, up 24% QoQ and 129% YoY

Delivered result: ₹6.6 Cr; QoQ +24%, YoY +129%

Supported

EBITDA margin expanding to 26.8% from 24.4% in Q1

Delivered OPM 26.8%; Q1 24.4%: 240 bps improvement confirmed

Supported

H1 PAT margin approximately 16.5% on ₹72.4 Cr revenue

Actual H1 PAT margin 16.4% (₹11.9 Cr ÷ ₹72.4 Cr); Q2 standalone 17.1%

Supported

Operating cash flow lag due to acquisition spend

H1 OCF ₹0.4 Cr vs PAT ₹11.9 Cr; ₹16.7 Cr capex + ₹40–42 Cr receivables both draining

Partially explained

What changed on this call

The bull-bear ledger

Ranked by how they should influence a holder
  • Acquisition model is working: 51%-stake-then-proof-of-concept template reduces greenfield capex and preserves operator incentives

  • YoY growth is real and substantial: 195% revenue, 129% PAT growth with no one-time items inflating profit

  • Case mix is shifting toward high-margin super-specialty (cardiac, ortho, renal) which commands 26%+ margins

  • Medical tourism play in Dubai is emerging upside and aligns with India's healthcare export potential

  • H1 operating cash flow of ₹0.4 Cr against ₹11.9 Cr PAT is a red flag: accrual-to-cash conversion is severely lagged

  • Receivables pile of ₹40–42 Cr is locking cash; government and insurance payment delays create recovery risk and potential bad-debt provision

  • Management refused all FY27 guidance despite strong Q2 momentum—signals internal uncertainty or lack of confidence in near-term assumptions

  • Acquisition pipeline (3 pending deals) has no disclosed timelines, values, or probability; compounds execution risk if integrations draw capex upfront

  • Consolidated margin ceiling at 26.8% is structurally lower than pre-acquisition core (26.8% vs. 32.8%) and will remain compressed until acquired units scale

Ranked risks—what should concern a holder most

Working capital and cash conversion collapse

High

H1 OCF ₹0.4 Cr vs PAT ₹11.9 Cr exposes underlying liquidity stress. Receivables (₹40–42 Cr) and acquisition capex (₹16.7 Cr) are both drains. If further acquisitions close in H2 without cash flow recovery, liquidity will tighten. Net debt sits at ₹263.6 Cr, and cash generation is the acid test for leverage sustainability.

Acquisition integration complexity and execution risk

High

Blue Tree Dubai is now live but diluting consolidated margins (employee costs up 41% in Q1). Three more targets in pipeline (Globally Dubai, Rai Farm Bharuch, Patel Multispecialty Ankleswar) with no disclosed timelines. Sequential closings without proof of integration success could compound capex demand and management distraction.

Receivables aging and payment delays

High

₹40–42 Cr accumulated receivables represent 55–59% of Q2 quarterly revenue—a significant portion of collected cash. Government payers delay 6+ months; insurance disputes extend timelines further. If bad-debt provisions become necessary or if discounting deepens to accelerate collection, profitability will suffer.

Margin compression from lower-margin acquired hospitals

Medium

Core GKSL ran 32.8% EBITDA margin in FY26; consolidated is now 26.8%. Until acquired units reach core profitability, consolidated margin is capped. Management acknowledged margins will 'fluctuate' and 'average' but provided no timeline for uplift.

Seasonality volatility and revenue unpredictability

Medium

Management flagged quarter-to-quarter variance due to festivals, doctor's leave, and patient flow. Q1 typically high, Q2–Q3 soft. This makes run-rate extrapolation unreliable—which may explain why management refused to quantify FY27.

How the market is positioned

The stock has already repriced the story: price stands at ₹154.87, down 26.18% from its all-time high of ₹209.8. It trades below its 20-day SMA (₹172.9) and 50-day SMA (₹175.13), but above the 200-day (₹135.75), suggesting a pullback from overbought but support holding. RSI at 30.4 is neutral to slightly oversold. FII flows tell the story: foreign ownership collapsed from 10.47% in Q3 FY26 to 4.88% in Q1 FY27, a 560-basis-point exodus. DII held steady at 0.56–1.67%; promoter stake locked at 71.45%. Bulk deals over six months show FII exits (Nexus Global sold ₹4.4 lakh shares at ₹178) and insider rebalancing. The verdict of the market is clear: growth is real, but not credible enough to justify premium valuations when cash flow is broken and guidance is silent. The 26% drawdown from ATH suggests consensus has priced in acquisition integration risk and cash flow concerns. The call's lack of FY27 guidance reinforced that skepticism rather than alleviating it.

The debate

What to watch next

Three concrete things that resolve the debate next quarter
  • 1 · Q3 seasonality and collection tightening

    Management flagged Q1 high, Q2–Q3 soft due to festival and summer effects. Q3 is a real test of collection discipline promised from 1 April onward. If H1 receivables begin to age down and Q3 operating cash flow moves materially above ₹0.4 Cr, fears about cash drain are allayed. Watch: Q3 receivables aging and operating cash flow. Threshold: OCF should improve to ₹1.5–2.0 Cr+ to signal credible recovery.

  • 2 · H2 acquisition close timelines and execution

    The pipeline has three targets (Globally Dubai, Rai Farm Bharuch, Patel Multispecialty Ankleswar) with no disclosed timelines. Management cited NDAs but offered no visibility. Explicit timelines would either (a) prove execution confidence and unlock upside, or (b) trigger capex pressure that amplifies cash concerns. Watch: management commentary on acquisition status in Q3 results or annual report. Threshold: concrete timelines and valuations would rebuild credibility.

  • 3 · FY27 full-year guidance or admission of platform constraints

    Management refused FY27 guidance citing 'platform constraints.' At year-end, they must deliver either quantified FY27 revenue/margin targets or admit that internal uncertainty is structural. Even a conservative guide (e.g., ₹155–165 Cr FY27 revenue, 25–27% EBITDA margin) would rebuild credibility. Watch: management's tone on FY27 guidance in Q3 results. If they provide it, that's a psychological reset. If they deflect again, skepticism deepens.

The verdict

Q2 is a genuine growth quarter: revenue and profit are up in double or triple digits on real acquisition consolidation, margins are expanding, and management is executing on a disciplined M&A playbook. But this quarter is a steady state, not a step change. The real story is not the headline growth—it's the severe gap between accrual profit and cash generation, the receivables pile that is locking liquidity, and management's silence on FY27 guidance, which signals internal uncertainty or lack of conviction. The market has already repriced: the stock is down 26% from ATH, FII has exited aggressively, and the technical picture is neutral to bearish. Holders who believe in the acquisition model and can tolerate quarterly variance should Hold. New buyers should wait for proof of H2 cash conversion and explicit FY27 guidance before adding. The number to track from here is operating cash flow—if it stays sub-₹1 Cr in H2, the integration playbook is not converting accruals to cash, and the growth story becomes a liability rather than an asset.

Informational and educational content only. Not investment advice.